Are alkylating agents a necessary component in the therapy of Hodgkin's disease.

Abstract:

:Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses have good results when treated with radiotherapy alone, patients with adverse features need chemotherapy for optimal disease-free survival results. MOPP and its variants have been studied extensively for adjuvant therapy of patients with early staged disease but are associated with the development of secondary malignancies, including acute leukemia and solid tumors. ABVD has been compared with MOPP in combination with radiation therapy for patients with stages IIB and IIIB, and ABVD is not associated with a high risk of acute leukemia; however, cardiac and pulmonary toxicities have been reported, and there may be long term complications following ABVD in combined modality programs. In 1988, we developed NOVP [mitoxantrone (Novantrone), vincristine, vinblastine, prednisone], designed as adjuvant chemotherapy to treat patients with clinically staged I-II Hodgkin's disease who had unfavorable features, including B symptoms, large mediastinal masses, and hilar lymph node involvement. We also included patients with peripheral masses > or = 10 cms and those with stage III disease. In the second phase of this study, we treated patients without adverse features, in order to avoid laparotomy. The treatment plan included three cycles of NOVP, followed by radiotherapy to the mantle and the abdomen, with fields depending upon disease presentation. Patients with large mediastinal masses or hilar involvement also received low dose lung radiotherapy.(ABSTRACT TRUNCATED AT 250 WORDS)

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Hagemeister FB

doi

10.3109/10428199309149119

subject

Has Abstract

pub_date

1993-01-01 00:00:00

pages

91-7

eissn

1042-8194

issn

1029-2403

journal_volume

10 Suppl

pub_type

杂志文章
  • Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.

    abstract::Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428191003721342

    authors: Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

    更新日期:2010-06-01 00:00:00

  • Establishment and characterization of a new Ph1-positive ALL cell line (ALL/MIK) presenting bcr gene rearrangement on bcr-2 and ALL-type bcr/abl transcript: suggestion of in vitro differentiation to monocytoid lineage.

    abstract::A new Ph1-positive acute lymphoblastic leukemia cell line, designated as ALL/MIK, has been developed from a patient with Ph1-positive acute leukemia. The ALL/MIK cells showed an immunophenotype of common ALL with rearranged JH and Jk genes. The ALL/MIK cells showed no M-bcr rearrangement using Southern blot analysis w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409059601

    authors: Higa T,Okabe M,Kunieda Y,Kodama S,Itaya T,Kurosawa M,Sakurada K,Maekawa I,Shoji M,Kasai M

    更新日期:1994-01-01 00:00:00

  • Biological response modifiers render tumor cells susceptible to autologous effector mechanisms by influencing adhesion receptors.

    abstract::Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309147353

    authors: Schirren CA,Völpel H,Hoffmann JC,Henning SW,Qiao L,Autschbach F,Dengler TJ,Döhner H,Meuer SC

    更新日期:1993-05-01 00:00:00

  • Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications.

    abstract::Apoptosis, the caspase-mediated cell death, plays an important role in the etiology, pathogenesis and therapy of a variety of diseases. Abnormalities of apoptosis regulation, resulting in either its inhibition or enhancement, play a key role in the development of various malignant hematological disorders. Several rout...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000077007

    authors: Smolewski P,Darzynkiewicz Z,Robak T

    更新日期:2003-07-01 00:00:00

  • The Wilms tumour gene WT1 in leukaemia.

    abstract::The WT1 gene is essential for kidney development and is mutated in some Wilms tumours. It is also expressed at a high level in many acute leukaemias and in some haematopoietic progenitor cells, and mutations have been found in leukaemias. The function of WT1, which is a zinc finger protein and has domains characterist...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709059677

    authors: Pritchard-Jones K,King-Underwood L

    更新日期:1997-10-01 00:00:00

  • Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: results of a pilot study.

    abstract::This study was designed to investigate the immunostimulatory effect of low dose Il-2 treatment in B-CLL patients previously treated with 2-chlorodeoxyadenosine (2CdA) in whom severe depletion of T lymphocyte subsets was observed. Four patients enrolled into the study had previously been treated with 3-6 courses of 2Cd...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199909050958

    authors: Dmoszyńska A,Legiec W,Wach M

    更新日期:1999-07-01 00:00:00

  • Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia.

    abstract::Bullous pyoderma gangrenosum begins as a bulla, nodule or nonulcerated erythematous plaque that blisters or ulcerates to form a superficial ulcer surrounded by a hemorrhagic, bullous border, which is surrounded by a blue-gray halo. Bullous pyoderma gangrenosum is most commonly associated with hematologic malignancies,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500254299

    authors: Fox LP,Geyer AS,Husain S,Grossman ME

    更新日期:2006-01-01 00:00:00

  • Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis.

    abstract::Multiple myeloma (MM) often presents with unspecific symptoms and is challenging to diagnose. We performed this DSMM/EMN-analysis via test-(retro-) and validation (prospective) study to determine the time interval from the onset of first symptoms to the diagnosis of MM. The retrospective and prospective analyses were ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1695051

    authors: Graziani G,Herget GW,Ihorst G,Zeissig M,Chaidos A,Auner HW,Duyster J,Wäsch R,Engelhardt M

    更新日期:2020-04-01 00:00:00

  • Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.

    abstract::Progress in chronic lymphocytic leukemia (CLL) therapies has extended greatly the length and depth of remission, with the goal of treatment advancing towards a cure for some patients. Accordingly, clinical endpoints must evolve to capture these outcomes, and to provide faster access to novel therapies. Minimal residua...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1318439

    authors: Owen C,Christofides A,Johnson N,Lawrence T,MacDonald D,Ward C

    更新日期:2017-12-01 00:00:00

  • Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution.

    abstract::Peripheral T-cell lymphomas are characterized by a poor clinical outcome. We retrospectively analyzed 208 adults treated in our institution between 2000 and 2011. Median age at diagnosis was 55 years. Fifty-one percent had B symptoms and 51% serum elevated lactate dehydrogenase (LDH) levels. Eastern Cooperative Oncolo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.776680

    authors: Broussais-Guillaumot F,Coso D,Belmecheri N,Ivanov V,Schiano de Collela JM,Aurran-Schleinitz T,Stoppa AM,Chetaille B,Xerri L,Esterni B,Blaise D,Bouabdallah R

    更新日期:2013-11-01 00:00:00

  • Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.

    abstract::The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.588761

    authors: Hong J,Park S,Park J,Kim HS,Kim KH,Ahn JY,Rim MY,Jung M,Sym SJ,Cho EK,Shin DB,Lee JH

    更新日期:2011-10-01 00:00:00

  • The persistence of t(14;18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for 'a lymphoma stem cell'.

    abstract::Monitoring of t(14;18) in blood or bone marrow in follicular lymphoma (FL) remains controversial. We attempted to monitor t(14;18) in lymph nodes by ultrasound-guided fine needle aspirations (UG-FNA). First, we confirmed t(14;18) in 27/31 UG-FNAs of lymph nodes with fluorescent in situ hybridisation (FISH) and/or poly...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902927005

    authors: Janikova A,Mayer J,Kren L,Smardova J,Dvorakova D,Neubauer J,Vasova I

    更新日期:2009-07-01 00:00:00

  • Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis.

    abstract::The human analogue of the mouse double minute-2 (MDM-2) protein binds to p53 protein and abrogates its tumor-suppressing activity. MDM-2 overexpression may represent an alternative mechanism to p53 mutation for escaping the p53-mediated growth control. Interestingly, multiple MDM-2 protein isoforms have been described...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509051698

    authors: Bueso-Ramos CE,Manshouri T,Haidar MA,Huh YO,Keating MJ,Albitar M

    更新日期:1995-03-01 00:00:00

  • Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification.

    abstract::The purpose of this study was to better define the clinical features and natural history of peripheral T-cell lymphomas (PTCL) entities included in the Revised European American lymphoma (REAL) classification. Cases of PTCL were retrieved from the records of the Department of Pathology and classified according to the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000030054

    authors: Arrowsmith ER,Macon WR,Kinney MC,Stein RS,Goodman SA,Morgan DS,Flexner JM,Cousar JB,Jagasia MH,McCurley TL,Greer JP

    更新日期:2003-02-01 00:00:00

  • Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.

    abstract::Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone),...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.546016

    authors: Borchmann P,Herbrecht R,Wilhelm M,Morschhauser F,Hess G,Cernohous P,Veals SA,Singer JW,Engert A

    更新日期:2011-04-01 00:00:00

  • Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma.

    abstract::The human germinal center-associated lymphoma (HGAL) gene has prognostic value in diffuse large B-cell lymphoma, and expression of its cognate protein is germinal center-specific. A previous study had suggested that HGAL protein expression might also be related to the outcome in patients with Hodgkin lymphoma (HL). Th...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903242628

    authors: Azambuja D,Lossos IS,Biasoli I,Morais JC,Britto L,Scheliga A,Pulcheri W,Natkunam Y,Spector N

    更新日期:2009-11-01 00:00:00

  • Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.

    abstract::Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diag...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.963080

    authors: Movassaghian M,Brunner AM,Blonquist TM,Sadrzadeh H,Bhatia A,Perry AM,Attar EC,Amrein PC,Ballen KK,Neuberg DS,Fathi AT

    更新日期:2015-06-01 00:00:00

  • Transition of polycythemia vera to chronic neutrophilic leukemia.

    abstract::Two cases of polycythemia vera (PV) had transition to a hematological condition compatible with chronic neutrophilic leukemia (CNL) 17 and 8 years after diagnosis, respectively. One patient was treated with carboquone followed by hydroxyurea (HU) and the other with HU during PV phase. On transition, both had neutrophi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909093744

    authors: Higuchi T,Oba R,Endo M,Harada H,Mori H,Niikura H,Omine M,Fujita K

    更新日期:1999-03-01 00:00:00

  • Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.

    abstract::131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia (CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN gamma. In study, 1, 13 not pretreated and 41 pretreated patients, 48 in chronic phase disease, 6 in accelerated phase, received 4 x 10(6) U/m2 IFN a...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199309148513

    authors: Niederle N,Kloke O,Wandl UB,Becher R,Moritz T,Opalka B

    更新日期:1993-01-01 00:00:00

  • The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.

    abstract::Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy with a poor survival despite aggressive multiagent chemotherapy. The combination of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has been reported to induce remissions in patients with ATL. The purpose of this s...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428190109057927

    authors: White JD,Wharfe G,Stewart DM,Maher VE,Eicher D,Herring B,Derby M,Jackson-Booth PG,Marshall M,Lucy D,Jain A,Cranston B,Hanchard B,Lee CC,Top LE,Fleisher TA,Nelson DL,Waldmann TA

    更新日期:2001-01-01 00:00:00

  • Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF).

    abstract::The aim of the present study was to evaluate the efficacy of the combination of fludarabine 30/mg/m2 + cytarabine 2g/m2 followed by the administration of G-CSF to achieve a complete remission (CR) in patients with relapsed acute lymphoblastic leukemia (ALL). We treated twelve patients in first relapse, overall 10 pati...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199709039047

    authors: Montillo M,Tedeschi A,Centurioni R,Leoni P

    更新日期:1997-05-01 00:00:00

  • Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas.

    abstract::There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000006277

    authors: Lee HK,Wilder RB,Jones D,Ha CS,Pro B,Rodriguez MA,Romaguera JE,Cabanillas F,Rodriguez J,Cox JD

    更新日期:2002-09-01 00:00:00

  • Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.

    abstract::Since unlimited proliferative potential has been identified as a major and, to date, therapeutically unexploited phenotypic hallmark of cancer, telomere maintenance mechanisms have been proposed as potential targets for new anticancer interventions. This study was aimed to investigate the effects of BIBR1532, the lead...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.704034

    authors: Bashash D,Ghaffari SH,Mirzaee R,Alimoghaddam K,Ghavamzadeh A

    更新日期:2013-03-01 00:00:00

  • Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.

    abstract::High-dose melphalan therapy with peripheral blood stem cell (PBSC) transplantation is a standard treatment for younger patients with untreated multiple myeloma that results in high overall and complete response (CR) rates, and improved event-free and overall survival compared with standard chemotherapy alone. Inductio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190701540991

    authors: Oakervee H,Popat R,Cavenagh JD

    更新日期:2007-10-01 00:00:00

  • Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.

    abstract::B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000006411

    authors: Wang P,Pavletic ZS,Joshi SS

    更新日期:2002-09-01 00:00:00

  • Allergic reactions associated with pegaspargase in adults.

    abstract::One of the severe toxicities of pegaspargase (PEG) is the development of allergic reactions. This study retrospectively assessed 311 PEG doses administered to 139 acute lymphoblastic leukemia patients from May 1, 2008 to July 30, 2014 for allergic reactions based on the Common Terminology Criteria for Adverse Events (...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1105369

    authors: Chang A,Kim M,Seyer M,Patel S

    更新日期:2016-07-01 00:00:00

  • Evidence for a seasonal variation in the presentation of Hodgkins disease.

    abstract::An analysis by month of diagnosis was made of 1359 cases of Hodgkins disease (HD) on the Scotland and Newcastle Lymphoma Group (SNLG) registry 1979-1992 to look for evidence of seasonality. A March peak was evident when all cases were analysed (p < 0.01). The histological subtypes nodular sclerosing (NS) and mixed cel...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509059625

    authors: Neilly IJ,Dawson AA,Bennett B,Douglas S

    更新日期:1995-07-01 00:00:00

  • Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma.

    abstract::The patient granulocyte-colony stimulating factor (G-CSF) response is represented by the leukocyte peak in the blood induced by a single dose of G-CSF after chemotherapy, and is correlated with subsequent neutropenic infection risk. General patterns for a meaningful risk group stratification, have not yet been determi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2014.919631

    authors: Straka C,Salwender H,Schnabel B,Sandherr M,Wandt H,Hübel K,Scheid C,Metzner B,Hentrich M,Franke D,Weidenegger G,Freund M,Sezer O,Einsele H,Hinke A,Emmerich B

    更新日期:2015-02-01 00:00:00

  • The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription.

    abstract::Imatinib, which has revolutionized chronic myeloid leukemia (CML) treatment, was suggested to improve lipid profile. Statins, a dyslipidemia drug, were reported to potentiate imatinib's antileukemic effect. However, analysis of imatinib combined with statins is lacking. We have retrospectively analyzed the normalizati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1228928

    authors: Ellis M,Krashin E,Hamburger-Avnery O,Gan S,Elis A,Ashur-Fabian O

    更新日期:2017-05-01 00:00:00

  • Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes.

    abstract::Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematologi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2015.1028053

    authors: Sánchez-Castro J,Marco-Betés V,Gómez-Arbonés X,García-Cerecedo T,López R,Talavera E,Fernández-Ruiz S,Ademà V,Marugan I,Luño E,Sanzo C,Vallespí T,Arenillas L,Marco Buades J,Batlle A,Buño I,Martín Ramos ML,Blázquez Rios B

    更新日期:2015-01-01 00:00:00